FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.36 USD
+0.02 (6.02%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.36 USD
+0.02 (6.02%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Zacks News
FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia
by Zacks Equity Research
FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.
Tyme Initiates Pivotal Stage of Pancreatic Cancer Study
by Zacks Equity Research
Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.
BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors
by Zacks Equity Research
BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.
Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa
by Zacks Equity Research
The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs
by Zacks Equity Research
Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.
FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD
by Zacks Equity Research
FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent patients.
Zacks.com featured highlights include: ACM, FibroGen, Funko, Matrix Service and PetIQ
by Zacks Equity Research
Zacks.com featured highlights include: ACM, FibroGen, Funko, Matrix Service and PetIQ
What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell?
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
5 Stocks with High Net Income Ratio to Grab Now
by Nitish Marwah
Investors always have a keen eye for companies having a high level of profitability regardless of the market condition.
Theravance Announces Positive Early Data on JAK Inhibitor
by Zacks Equity Research
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)
by Zacks Equity Research
Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.
Endo International Files BLA for Label Expansion of Xiaflex
by Zacks Equity Research
Endo International (ENDP) files BLA for the additional indication of Xiaflex [collagenase clostridium histolyticum (CCH)] for the treatment of cellulite in the buttocks.
Radius (RDUS) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Radius (RDUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Ensign Group to Spin Off Home Health & Hospice Business
by Zacks Equity Research
Ensign Group (ENSG) to separate its home health and hospice business from the parent company.
FibroGen (FGEN) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
FibroGen (FGEN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
by Zacks Equity Research
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta
by Zacks Equity Research
The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.
Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4
by Zacks Equity Research
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
Tilray (TLRY) Catches Eye: Stock Jumps 8.4%
by Zacks Equity Research
Tilray (TLRY) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
FibroGen (FGEN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 357.14% and 492.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for FibroGen (FGEN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to FibroGen (FGEN) stock based on the movements in the options market lately.
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 22.06% and 19.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss
by Zacks Equity Research
Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.